GLPG0555 clinical trials
Also written GLPG0555.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses GLPG0555 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GLPG0555
- 2
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses GLPG0555 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Oral Bioavailability of GLPG0555 in Different Solid FormulationsCompletedPhase 1Galapagos NVNCT01278095Written as GLPG0555 solid dispersion
- Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy SubjectsCompletedPhase 1Galapagos NVNCT01208753Written as GLPG0555
- First-in-Human Single Ascending and Multiple Dose of GLPG0555CompletedPhase 1Galapagos NVNCT01023321Written as GLPG0555